

## ORIGINAL ARTICLE

# Curcumin inhibits proliferation and invasion of papillary thyroid carcinoma cells by inhibiting the JAK2 / STAT3 pathway

Ying Hu<sup>1</sup>, Ning Zhou<sup>2</sup>, Qiongwen Zhu<sup>3</sup>

<sup>1</sup>Clinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China. <sup>2</sup>Department of Geriatrics Medicine, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China. <sup>3</sup>Department of Pharmacy, Geriatric Care Hospital Zhejiang, Hangzhou, China.

## Summary

**Purpose:** The purpose of this study was to analyze the function of curcumin to suppress the proliferative and invasive abilities of papillary thyroid carcinoma (PTC) through inhibiting the JAK2/STAT3 pathway.

**Methods:** After treatment of different doses of curcumin in TPC-1 and SW1736 cells, changes in viability, clonality, cell cycle, apoptosis, wound healing and invasion were determined. Western blot analyses were performed to detect protein levels of apoptosis-associated genes, JAK2 and STAT3 in TPC-1 and SW1736 cells treated with different doses of curcumin.

**Results:** Curcumin treatment dose-dependently reduced viability, clonality and metastatic ability in TPC-1 and SW1736 cells. After treatment of 10  $\mu$ M or 20  $\mu$ M curcumin, PTC cells were blocked in G2/M phase, and their apoptotic rate increased. Curcumin treatment downregulated Bcl-2 and upregulated Bax in PTC cells. In addition, curcumin treatment downregulated p-JAK2 and p-STAT3 in TPC-1 and SW1736 cells.

**Conclusions:** Curcumin treatment blocks PTC cells to proliferate and invade via inhibiting the JAK2/STAT3 pathway.

**Key words:** curcumin, PTC, proliferation, invasion

## Introduction

As the most common malignancy of the endocrine system, thyroid carcinoma accounts for about 1% of the total number of malignant tumors [1]. Papillary thyroid carcinoma (PTC) is the leading prevalent subtype, accounting for approximately 80% of all thyroid cancer cases [2]. Generally speaking, patients with early-stage PTC have a very good prognosis after surgery. The 5-year survival of PTC is up to 97%. Nevertheless, 10-15% of PTC patients have a poor prognosis due to distant metastasis and recurrence [3]. Currently, clinical treatments for PTC include surgical resection, radioactive I-131 therapy [4], chemotherapy and combination therapy [5]. Most of therapeutic strategies for PTC

show great efficacy. However, a small part of PTC patients, especially those carrying BRAFV600E mutation, suffer of poor outcome and high rate of recurrence [6]. Therefore, it is necessary to develop effective drugs targeting PTC. Natural medicines are characterized with extensive efficacy, low toxicity and low cost, and have been well concerned as promising anti-tumor drugs.

Main phytochemicals in the diet have been highlighted due to their obvious safety and effectiveness [7]. Curcumin is a polyphenolic compound extracted from the roots of *Curcuma Longa*, which has been applied in the traditional Chinese Medicine for a long period [8]. The anti-proliferation,

Corresponding author: Ying Hu, MM. Clinical Pharmacy Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, 158 Shangtang Rd, Hangzhou, Zhejiang 310014, China.  
Tel: +86 018857175517; Email: daisytinglan@163.com  
Received: 29/04/2021; Accepted: 22/05/2021

anti-oxidant, anti-inflammatory and anti-tumor properties of curcumin have been identified [9]. In many types of tumors, curcumin exerts extraordinary anti-tumor activities through regulating tumor cell behaviors [10-12]. Importantly, clinical trials have proved its low toxicity and high safety. Uncontrolled proliferation and apoptosis would accelerate the malignant progression of tumors [13,14]. A previous study demonstrated the inhibitory effect of curcumin on PTC progression through blocking its proliferative ability and inducing apoptosis [15]. In K1 PTC, curcumin administration suppresses invasion and metastasis of tumor cells [16,17]. Curcumin is able to inhibit hypoxia-induced migratory acceleration in PTC as well [18].

In this paper, we mainly explored the potential function of curcumin in affecting many phenotypes of PTC cells and the underlying mechanism.


## Methods

### Cell culture

PTC cells TPC-1 and SW1736 were purchased from Cell Bank (Shanghai, China). Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, Rockville, MD, USA) containing 10% fetal bovine serum (FBS) (Gibco, Rockville, MD, USA), 100 U/mL penicillin and 100 µg/mL streptomycin. Curcumin (99% purity, Sigma-Aldrich Co., St. Louis, MO, USA) was diluted in dimethyl sulfoxide (DMSO), and preserved at -20°C in the dark. PTC cells were treated with 5, 10 or 20 µM curcumin for 24 h, respectively.

### Cell counting kit-8 (CCK-8)

Cells were inoculated in 96-well plates with  $2 \times 10^5$  cells/well. At the appointed time points, absorbance value at 450 nm of each sample was recorded using the CCK-8 kit (Dojindo Laboratories, Kumamoto, Japan) for plotting the viability curves.



**Figure 1.** Curcumin treatment dose-dependently inhibited proliferative ability in PTC. **A:** Viability in TPC-1 and SW1736 cells and **B:** after 0, 5, 10 or 20 µM curcumin treatment for 24 h. **C:** Relative colony number in TPC-1 and SW1736 cells and **D:** after 0, 10 or 20 µM curcumin treatment for 24 h.

### Colony formation assay

$1 \times 10^3$  cells/well were inoculated in 6-well plates, induced with different doses of curcumin for 24 h and cultured for 10 days. Afterwards, cells were fixed with 4% polyformaldehyde for 30 min and dyed with 0.1% crystal violet for 30 min. Visible colonies were finally captured.

### Cell cycle determination

Cells were washed with phosphate buffered saline (PBS) twice, digested and prepared to cell suspension with  $1 \times 10^5$ /mL. After fixation in 70% ethanol, cells were dyed with 500  $\mu$ L of propidium iodide (PI) at 4°C, in the dark for 15 min. Finally, cell cycle distribution was analyzed.

### Flow cytometry

Cells were washed with PBS twice, digested and prepared to cell suspension with  $1 \times 10^5$ /mL. Cells were incubated in 1 ml of pre-cold 70% ethanol at 4°C overnight. In the next day, cells were incubated with 100  $\mu$ L


of RNaseA at 37°C, in the dark for 30-min water bath. Subsequently, cells were dyed with 500  $\mu$ L of PI at 4°C in the dark for 15 min and finally the apoptotic rate was determined at 488 nm wavelength.

### Western blot

Cellular protein was isolated using radioimmuno-precipitation assay (RIPA) and electrophoresed. Protein sample was loaded on polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA), which were immersed in PBS containing 5% skim milk for 2 h, reacted with primary antibodies at 4°C overnight and secondary antibodies for 2 h. Band exposure was achieved by electrochemiluminescence (ECL) and processed by Image Software (NIH, Bethesda, MD, USA).

### Wound healing assay

Cells were seeded in 6-well plates with  $1.0 \times 10^6$  cells/well. An artificial wound was created in the confluent cell monolayer using a 100  $\mu$ L pipette tip. Wound closure was captured at 0 and 24 h for calculating the percentage of wound width.



**Figure 2.** Curcumin treatment induced apoptosis in PTC. **A,B:** Cell cycle distribution in TPC-1 (**A**) and SW1736 cells (**B**) after 0, 10 or 20  $\mu$ M curcumin treatment for 24 h. **C,D:** Apoptotic rate in TPC-1 (**C**) and SW1736 cells (**D**) after 0, 10 or 20  $\mu$ M curcumin treatment for 24 h. **E:** Protein levels of Bcl-2 and Bax in TPC-1 and SW1736 cells after 0, 10 or 20  $\mu$ M curcumin treatment for 24 h.

### Transwell assay

$3 \times 10^4$  cells were inoculated on the top of a transwell insert placed in 24-well plates while 100  $\mu$ L of serum-free medium was applied in the bottom. After 24-h incubation, cells invaded to the bottom side were immersed in methanol for 15 min, dyed with crystal violet for 20 min and counted using a microscope. Invasive cell number was counted in 5 randomly selected fields per sample (magnification 40 $\times$ ).

### Statistics

SPSS 22.0 (IBM, Armonk, NY, USA) was used for statistical analyses. Data were expressed as mean  $\pm$  SD (standard deviation). Comparison between multiple groups was done using one-way ANOVA test followed by *post hoc* test (least significant difference).  $P < 0.05$  indicated significant difference.

## Results

### Curcumin treatment dose-dependently inhibited proliferative ability in PTC

To uncover potential influences of curcumin on the proliferation of PTC, TPC-1 and SW1736 cells were treated with 0, 5, 10 or 20  $\mu$ M curcumin for 24 h, respectively. CCK-8 results depicted a dose-dependent decline in cell viability (Figures 1A,1B). Meanwhile, relative colony numbers were reduced after 0, 10 or 20  $\mu$ M curcumin treatment for 24 h (Fig-


ures 1C,1D). Therefore, curcumin treatment dose-dependently attenuated the proliferative ability in PTC.

### Curcumin treatment induced apoptosis in PTC

TPC-1 and SW1736 cells were treated with 0, 10 or 20  $\mu$ M curcumin for 24 h. Flow cytometry revealed that cells were remarkably arrested in G2/M phase after curcumin treatment (Figures 2A,2B). The apoptotic rate was dose-dependently elevated in PTC cells treated with 10 or 20  $\mu$ M curcumin for 24 h (Figures 2C,2D). In addition, western blot analyses showed that Bcl-2 was gradually downregulated, while Bax was dose-dependently upregulated in PTC cells following curcumin treatment (Figure 2E). It is suggested that the apoptotic ability of PTC was stimulated by curcumin treatment.

### Curcumin treatment dose-dependently inhibited migratory and invasive abilities in PTC

Metastatic ability changes in PTC influenced by curcumin treatment were assessed by wound healing assay and transwell assay. The percentage of wound width gradually increased in PTC cells treated with 0, 10, and 20  $\mu$ M curcumin, respectively, revealing the suppressed migratory ability (Figures 3A,3B). Transwell assay revealed a dose-dependent decline in invasive cell number after curcumin treatment (Figures 3C,3D).



**Figure 3.** Curcumin treatment dose-dependently inhibited migratory and invasive abilities in PTC. **A,B:** Percentage of wound width in TPC-1 (**A**) and SW1736 cells (**B**) after 0, 10 or 20  $\mu$ M curcumin treatment for 24 h. **C,D:** Invasive cell number in TPC-1 (**C**) and SW1736 cells (**D**) after 0, 10 or 20  $\mu$ M curcumin treatment for 24 h.

### Curcumin treatment inactivated the JAK2/STAT3 pathway


The JAK/STAT3 pathway is critical during the malignant progression of PTC [19]. Herein, we determined protein levels of p-JAK2, JAK2, p-STAT3 and STAT3 in curcumin-treated TPC-1 and SW1736 cells. Curcumin treatment dose-dependently reduced the ratios of p-JAK2/t-JAK2 and p-STAT3/t-STAT3 in TPC-1 and SW1736 cells, showing suppressed JAK2/STAT3 pathway (Figures 4A,4B).

### Discussion

The incidence of thyroid carcinoma has increased significantly in the past decade. PTC is the major subtype of thyroid carcinoma [20]. Surgical resection and radioactive I-131 therapy are the two effective strategies for PTC. However, tumor metastasis and recurrence increase the risk of surgical procedures and limit the prognosis of PTC [21]. Drugs that could effectively inhibit PTC metastasis are urgently required.

Curcumin is an active ingredient of Curcuma Longa with a variety of pharmacological activities [22]. Curcumin is capable of suppressing invasive and migratory abilities of many types of tumor cells [23]. Tumor metastasis is a complex, multi-step process. Initially, tumor cells invade, migrate and infiltrate other regions, and thus the distant colonization triggers tumor angiogenesis and the formation of distant metastases [24]. In this study, curcumin treatment dose-dependently reduced viability, arrested cell cycle in G2/M phase and induced apoptosis in PTC. Meanwhile, curcumin treatment attenuated migratory and invasive abilities in PTC. We believed that curcumin treatment could effectively prevent metastasis of PTC.

The JAK/STAT pathway was initially discovered in the interferon pathway [25,26]. JAK2 is a tyrosine kinase involved in the JAK/STAT pathway and has been demonstrated to be able to induce tumor cell survival and angiogenesis [27,28]. STAT3 is closely related to tumor progression through affecting malignant phenotypes of tumor cells [29-



**Figure 4.** Curcumin treatment inactivated the JAK2/STAT3 pathway. Protein levels of p-JAK2, JAK2, p-STAT3 and STAT3 in TPC-1 after 0, 10 or 20  $\mu$ M curcumin treatment for 24 h. Curcumin markedly reduced the ratios of p-JAK2/t-JAK2 and p-STAT3/t-STAT3 in TPC-1 (A) and SW1736 (B) cells; \* $p$ <0.05.

31]. The abnormal activation of JAK/STAT pathway is proved to be related to many types of tumors [19,32-35]. Our findings illustrated that curcumin treatment reduced the ratios of p-JAK2/t-JAK2 and p-STAT3/t-STAT3 in TPC-1 and SW1736 cells, indicating the suppressed JAK-STAT pathway. Based on our results, it is suggested that curcumin treatment attenuated viability and metastasis in PTC through inactivating the JAK/STAT pathway.

## References

1. Ciavardelli D, Bellomo M, Consalvo A, Crescimanno C, Vella V. Metabolic Alterations of Thyroid Cancer as Potential Therapeutic Targets. *Biomed Res Int* 2017;2017:2545031.
2. Takano T. Natural history of thyroid cancer [Review]. *Endocr J* 2017;64:237-44.
3. Grant CS. Recurrence of papillary thyroid cancer after optimized surgery. *Gland Surg* 2015;4:52-62.
4. Jung SN, Lim HS, Liu L et al. LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals. *Sci Rep* 2018;8:2718.
5. Tan C, Zhang L, Cheng X et al. Curcumin inhibits hypoxia-induced migration in K1 papillary thyroid cancer cells. *Exp Biol Med (Maywood)* 2015;240:925-35.
6. Markovic I, Goran M, Buta M et al. Sentinel lymph node biopsy in clinically node negative patients with papillary thyroid carcinoma. *JBUON* 2020;25:376-82.
7. Weng CJ, Yen GC. Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. *Cancer Treat Rev* 2012;38:76-87.
8. Tan C, Zhang L, Cheng X et al. Curcumin inhibits hypoxia-induced migration in K1 papillary thyroid cancer cells. *Exp Biol Med (Maywood)* 2015;240:925-35.
9. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. *Cancer Lett* 2008;269:199-225.
10. Yang CL, Liu YY, Ma YG et al. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. *PLoS One* 2012;7:e37960.
11. Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. *Cancer Res* 2009;69:8958-66.
12. Ji C, Cao C, Lu S et al. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. *Cancer Chemother Pharmacol* 2008;62:857-65.
13. Krawczyk-Rusiecka K, Wojciechowska-Durczynska K, Cyniak-Magiarska A, Adamczewski Z, Galecka E, Lewinski A. COX-2 expression in papillary thyroid carcinoma (PTC) in cytological material obtained by fine needle aspiration biopsy (FNAB). *Thyroid Res* 2011;4:3.
14. Nix P, Nicolaides A, Coatesworth AP. Thyroid cancer review 1: presentation and investigation of thyroid cancer. *Int J Clin Pract* 2005;59:1340-4.
15. Song F, Zhang L, Yu HX et al. The mechanism underlying proliferation-inhibitory and apoptosis-inducing effects of curcumin on papillary thyroid cancer cells. *Food Chem* 2012;132:43-50.
16. Zhang CY, Zhang L, Yu HX, Bao JD, Sun Z, Lu RR. Curcumin inhibits invasion and metastasis in K1 papillary thyroid cancer cells. *Food Chem* 2013;139:1021-8.
17. Zhang CY, Zhang L, Yu HX, Bao JD, Lu RR. Curcumin inhibits the metastasis of K1 papillary thyroid cancer cells via modulating E-cadherin and matrix metalloproteinase-9 expression. *Biotechnol Lett* 2013;35:995-1000.
18. Tan C, Zhang L, Cheng X et al. Curcumin inhibits hypoxia-induced migration in K1 papillary thyroid cancer cells. *Exp Biol Med (Maywood)* 2015;240:925-35.
19. Pan XM, He XY, Yang YL et al. MiR-630 inhibits papillary thyroid carcinoma cell growth, metastasis, and epithelial-mesenchymal transition by suppressing JAK2/STAT3 signaling pathway. *Eur Rev Med Pharmacol Sci* 2019;23:2453-60.
20. Podnos YD, Smith DD, Wagman LD, Ellenhorn JD. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. *J Surg Oncol* 2007;96:3-7.
21. Grant CS. Recurrence of papillary thyroid cancer after optimized surgery. *Gland Surg* 2015;4:52-62.
22. Zhang C, Li B, Zhang X, Hazarika P, Aggarwal BB, Duvic M. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling. *J Invest Dermatol* 2010;130:2110-9.
23. Wang Z, Zhang K, Zhu Y, Wang D, Shao Y, Zhang J. Curcumin inhibits hypoxia-induced proliferation and invasion of MG-63 osteosarcoma cells via downregulating Notch1. *Mol Med Rep* 2017;15:1747-52.
24. Weng CJ, Yen GC. Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. *Cancer Treat Rev* 2012;38:76-87.

## Conclusions

Curcumin treatment blocks PTC cells to proliferate and invade *via* inhibiting the JAK2/STAT3 pathway.

## Conflict of interests

The authors declare no conflict of interests.

25. Wilks AF, Harpur AG, Kurban RR, Ralph SJ, Zurcher G, Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. *Mol Cell Biol* 1991;11:2057-65.
26. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. *Cell* 1992;70:313-22.
27. Teng Y, Ross JL, Cowell JK. The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. *JAK-STAT* 2014;3:e28086.
28. Liu RY, Zeng Y, Lei Z et al. JAK/STAT3 signaling is required for TGF-beta-induced epithelial-mesenchymal transition in lung cancer cells. *Int J Oncol* 2014;44:1643-51.
29. Avalle L, Pensa S, Regis G, Novelli F, Poli V. STAT1 and STAT3 in tumorigenesis: A matter of balance. *JAKSTAT* 2012;1:65-72.
30. Devarajan E, Huang S. STAT3 as a central regulator of tumor metastases. *Curr Mol Med* 2009;9:626-33.
31. Gu L, Dagvadorj A, Lutz J et al. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. *Am J Pathol* 2010;176:1959-72.
32. Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. *Drug Resist Updat* 2010;13:67-78.
33. Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. *Pharmgenomics Pers Med* 2014;7:203-15.
34. Duzagac F, Inan S, Ela SF et al. JAK/STAT pathway interacts with intercellular cell adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) while prostate cancer stem cells form tumor spheroids. *JBUON* 2015;20:1250-7.
35. Bi CL, Zhang YQ, Li B, Guo M, Fu YL. MicroRNA-520a-3p suppresses epithelial-mesenchymal transition, invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK/STAT signaling pathway. *J Cell Physiol* 2019;234:4054-67.